With more than 25 molecules in clinical use, monoclonal antibodies have finally come of age
as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010.
While delivering interesting results in the treatment of several major diseases including autoimmune,
cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are
generating a wealth of useful information, for instance about associations of clinical responses with Fc
receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some
functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics
and tissue accessibility as well as impaired interactions with the immune system. This review aims at
giving an overview of the current state of the art and describes the most promising avenues that are
followed for generating the next generation of antibody-based cancer therapeutics, with a special
emphasis on bispecific antibodies.
Keywords: Immunotherapy, Monoclonal antibodies, Pharmacokinetics, Cancer, Antibody engineering,
glycosylation, Fc receptors, Therapeutic antibodies, Intrabodies.
